Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – SWB:9IP1
This article provides financial information for Rocket Pharmaceuticals, Inc. (SWB:9IP1), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet.
Rocket Pharmaceuticals, Inc. Warrant 2023- on Rocket Pharmctc Financial Disclosures & SEC Filings
This article provides a comprehensive list of financial disclosures and SEC filings for Rocket Pharmaceuticals, Inc. (RCKTW), detailing various corporate events such as earnings reports, FDA announcements, and conference presentations spanning from 2024 to 2026. Key advancements in their cardiac gene therapy pipeline and financial updates, including cash runway extensions and regulatory approvals, are highlighted. The documents offer insights into the company's operational updates and financial performance for informed decision-making.
Rocket Pharmaceuticals (NASDAQ: RCKT) appoints new Principal Accounting Officer
Rocket Pharmaceuticals (NASDAQ: RCKT) has announced a change in its Principal Accounting Officer. John Militello resigned, effective July 7, 2026, and Joseph Manhede, currently Associate Vice President, Corporate Controller, will assume the role on July 8, 2026. Manhede, a CPA with extensive experience in biopharmaceutical finance, will transition into the position without new compensatory arrangements.
Rocket Pharmaceuticals Appoints Joseph Manhede as Principal Accounting Officer – SEC 8-K Filing June 2026
Rocket Pharmaceuticals (NASDAQ: RCKT) has announced significant leadership changes in its finance department. John Militello, VP of Finance and Principal Accounting Officer, has resigned, with his departure effective July 7, 2026. Joseph Manhede, who joined the company in April 2026 as Associate Vice President, Corporate Controller, will assume the role of Principal Accounting Officer starting July 8, 2026, with no new compensatory arrangements.
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2500 Growth Benchmark
Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) has been dropped from the Russell 2500 Growth Benchmark, as well as several other Russell indices including the Small Cap Comp Growth, 2000 Growth, and 3000E Growth benchmarks. Concurrently, the company was added to the Russell 3000E Index and Russell Microcap Index, and specifically to the Russell Microcap Value Benchmark Index. This reclassification reflects shifts in the company's market capitalization and growth profile according to Russell's indexing methodology.
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to Russell Microcap Value Benchmark Index
Rocket Pharmaceuticals, Inc. (RCKT) has been added to the Russell Microcap Value Benchmark Index. This news follows several other index adjustments, including being dropped from the Russell 2000 Growth and Russell 3000E Growth benchmarks, but added to the broader Russell 3000E Index and Russell Microcap Index. The company is a late-stage biotechnology firm specializing in gene therapies for rare diseases.
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2000 Growth Benchmark
Rocket Pharmaceuticals, Inc. (RCKT) has been dropped from the Russell 2000 Growth Benchmark. This news comes alongside other recent index adjustments, including being added to the Russell Microcap Value Benchmark Index and the Russell 3000E Index, while also being dropped from the Russell 3000E Growth Benchmark and the S&P Biotechnology Select Industry Index. The company is a late-stage biotechnology firm focused on developing gene therapies for rare diseases.
Price to earnings forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW
This article provides financial data for Rocket Pharmaceuticals, Inc. (RCKTW), specifically focusing on its forward price-to-earnings ratio. It indicates current valuation metrics within the Health Technology and Biotechnology sectors, as presented on the TradingView platform. The content primarily lists the stock symbol and references its financial standing without offering detailed analysis or specific figures.
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action
Levi & Korsinsky LLP has filed a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (RCKT) to recover losses for shareholders affected by alleged securities fraud between September 17, 2024, and May 26, 2025. The lawsuit claims Rocket Pharmaceuticals made misleading statements and failed to disclose critical information about serious adverse events, including a patient's death, during a clinical trial for RP-A501. Shareholders who suffered losses are encouraged to contact the law firm before August 11, 2025, to learn about their rights to participate in the class action.
Rocket Pharmaceuticals, Inc. (RCKT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 11, 2025
Levi & Korsinsky LLP has filed a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (RCKT), urging investors who suffered losses between February 27, 2025, and May 26, 2025, to contact them before August 11, 2025. The lawsuit alleges that Rocket made misleading statements and concealed material adverse facts regarding the safety of its RP-A501 clinical trial, specifically failing to disclose a protocol amendment and a subsequent patient death. This led to a significant drop in Rocket's stock price after the FDA placed a clinical hold on the study.
Price to sales forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW
This article provides a brief financial snippet for Rocket Pharmaceuticals, Inc. under the ticker RCKTW, specifically focusing on its forward price-to-sales ratio. The content is sparse, indicating no active trades and only displaying the stock's name and its listing on the Blue Ocean Alternative Trade System.
Price to sales forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT
This article provides the "Price to sales forward" metric for Rocket Pharmaceuticals, Inc. (RCKT) on the Nasdaq Stock Market. It is a financial data point presented by TradingView, with data sourced from ICE Data Services and FactSet. The page indicates that the market was closed at the time of viewing.
Rocket Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:9IP1)
This article provides an overview of Rocket Pharmaceuticals, Inc. (TRADEGATE:9IP1) financial actuals and analyst estimates. It includes details on income statements, balance sheets, cash flow, and valuation metrics, along with FAQs about its stock ticker, forecasts, historical prices, earnings reports, revenue, net income, dividends, and employee count. The article also provides guidance on how to buy Rocket Pharmaceuticals, Inc. stocks.
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT
This article focuses on the enterprise value to revenue forward metric for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). It appears to be a stub or data-oriented piece from TradingView, indicating financial analysis for the biotechnology company. The content primarily lists navigation and footer information, with the core financial data presumably appearing where "Period Value Change Change %" is present.
Price to sales forward of Rocket Pharmaceuticals, Inc. – TRADEGATE:9IP1
This article provides financial information for Rocket Pharmaceuticals, Inc. (TRADEGATE:9IP1) on TradingView, specifically focusing on its price-to-sales forward ratio. The content lists various financial data and tools available on the platform for this stock, such as overview, financials, news, and forecasts. The data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.
RCKT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Rocket Pharmaceuticals, Inc. (RCKT) stock, including current price, historical performance, and analyst predictions for its future price targets. It covers financial data such as earnings, revenue, market capitalization, and volatility, along with information on upcoming earnings reports and employee count. The article also touches on technical analysis and offers guidance on how to trade RCKT stocks.
Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?
Rocket Pharmaceuticals (RCKT) recently achieved two significant milestones: BofA Securities raised its price target to $10 with a Buy rating after the company restarted dosing for its RP-A501 program, and it completed the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million. These events boosted the company's pro forma cash position to $322.6 million, extending its operational runway through Q2 2028 and positioning it for potential recovery in its gene therapy development for rare pediatric diseases.
Price to book forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT
The article discusses the "Price to book forward" metric for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, but the specific value for this metric is not displayed in the provided content. The page also lists various services and features offered by TradingView.
Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?
Rocket Pharmaceuticals, Inc. (RCKT) is seeing positive momentum after a BofA Securities analyst raised its price target, citing the restart of RP-A501 dosing as a crucial step for recovery. The company further strengthened its financial position by selling a Rare Pediatric Disease Priority Review Voucher for $180 million, boosting its pro forma cash to $322.6 million and extending its operational runway through Q2 2028. RCKT specializes in developing one-time gene therapies for rare pediatric diseases.
Price to book forward of Rocket Pharmaceuticals, Inc. – TRADEGATE:9IP1
This article provides the "Price to book forward" for Rocket Pharmaceuticals, Inc. (TRADEGATE:9IP1) on the TradingView platform. It shows that the market is closed with no trades. The article also provides standard financial and market data from various sources like ICE Data Services and FactSet.
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off
Rocket Pharmaceuticals (RCKT) shares fell 22% despite the FDA approving its gene therapy, Kresladi, for a rare pediatric immune disorder and granting a Priority Review Voucher. Wall Street analysts from Wedbush and LifeSci Capital dismissed the sell-off as unjustified, reiterating "Outperform" ratings and highlighting the drug approval as a significant milestone and the voucher as a potential source of non-dilutive capital. Retail sentiment remained "extremely bullish" on Stocktwits even as the stock has dropped significantly over the past year.
RCKT - The Structural Disconnect Between Market Valuation and Operational Maturity
This article argues that Rocket Pharmaceuticals (RCKT) is significantly undervalued due to the market's failure to recognize its operational and technical maturity in gene therapy manufacturing. It highlights the commercial validation of its manufacturing process through FDA approval of Kresladi, the structural gross margin advantage gained from vertical integration, and the strategic completeness provided by its dual-engine (LV and AAV) platform. The author believes that upcoming data readouts and the company's financial resilience will compel a market re-rating from a speculative biotech to a high-margin pharmaceutical company.
Rocket Pharmaceuticals Inc (RCKT) Financial Health: Profitability & Balance Sheet Analysis
Rocket Pharmaceuticals Inc (RCKT) currently holds a financial score of 5.45, ranking 359 out of 388 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. The analysis from TradingKey highlights specific scores for Quality of Earnings (7.43), Operational Efficiency (4.00), Growth Potential (6.75), and Shareholder Returns (7.03), noting that some relevant data have not yet been disclosed by the company.
Rocket Pharmaceuticals Inc (RCKT) Valuation: PE, PB & Fair Value Analysis
Rocket Pharmaceuticals Inc (RCKT) currently has a valuation score of 6.72, placing it at 300 out of 389 in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.85, representing a significant change from its recent high and low. Data for P/B, P/S, and P/CF ratios have not been disclosed by the company.
Rocket Pharmaceuticals Inc (RCKTW) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Rocket Pharmaceuticals Inc (RCKTW)'s financial health, focusing on profitability and balance sheet aspects. It uses data from TradingKey's stock score, but notes that relevant financial data for key metrics like cash and cash equivalents, total assets, operating profit, and free cash flow have not yet been disclosed by the company. The overview confirms current trading data and market capitalization for the stock.
Rocket Pharmaceuticals Inc (RCKT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Rocket Pharmaceuticals Inc (RCKT) currently has an earnings forecast score of 6.86, ranking it 324th out of 389 in its industry. Analysts have set an average price target of $8.00 for RCKT, with a high of $16.00 and a low of $2.00, based on ratings from 14 analysts. The consensus analyst rating is "Hold," and the company's recent EPS outperformed expectations, with the next quarter's EPS projected at $0.18.
Rocket Pharmaceuticals Inc (RCKTW) Institutional Confidence
This article from TradingKey briefly highlights the "Institutional Confidence" score for Rocket Pharmaceuticals Inc (RCKTW). It notes that while a score was previously 0.00, relevant institutional shareholding and shareholder activity data have not yet been disclosed by the company. The page provides a snapshot of the stock's current price and basic market information.
Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass
Rocket Pharmaceuticals sold its rare pediatric disease priority review voucher for $180 million, which will be used to fund its pipeline, including a gene therapy for Danon disease. The FDA granted the voucher alongside the accelerated approval of Rocket's Kresladi, a gene therapy for LAD-1. The sale highlights the increasing value of these vouchers, which allow for a faster FDA review process.
Rocket Pharma updates cash position after selling priority review voucher
Rocket Pharma announced an update to its cash position after selling its priority review voucher. The company now expects its cash, cash equivalents, and investments to exceed $600 million at the end of the second quarter of 2026, an increase from its previous projection. This sale significantly strengthens Rocket Pharma's financial outlook.
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Rocket Pharmaceuticals (NASDAQ: RCKT) has announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million. The PRV was granted by the FDA following the approval of KRESLADI™, a gene therapy for severe LAD-I. This sale significantly boosts Rocket's cash reserves, with pro forma cash, cash equivalents, and investments increasing to approximately $322.6 million, which is expected to fund operations into Q2 2028.
Rocket Pharmaceuticals Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher For $180 Million
Rocket Pharmaceuticals announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million. The company, identified by the stock symbol RCKT, closed this significant transaction.
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Rocket Pharmaceuticals announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million. This non-dilutive financing, combined with existing cash, increases their pro forma cash, cash equivalents, and investments to approximately $322.6 million, expected to fund operations into the second quarter of 2028. The voucher was granted by the FDA after the approval of KRESLADI™, Rocket’s gene therapy for severe LAD-I.
Rocket Pharmaceuticals (NASDAQ: RCKT) sells priority review voucher for $180M, extends runway
Rocket Pharmaceuticals has sold its Rare Pediatric Disease Priority Review Voucher for $180 million cash, significantly boosting its financial runway. This non-dilutive capital increases the company's cash, cash equivalents, and investments to approximately $322.6 million, which is expected to fund operations into the second quarter of 2028. The voucher was granted following FDA approval of KRESLADI, Rocket’s gene therapy for severe leukocyte adhesion deficiency-I.
Rocket Pharmaceuticals completes $180 million priority review voucher sale
Rocket Pharmaceuticals (NASDAQ: RCKT) has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million. The voucher was granted by the FDA after the approval of KRESLADI, a gene therapy for severe leukocyte adhesion deficiency-I. This sale boosts the company's pro forma cash position to approximately $322.6 million, expected to fund operations through Q2 2028.
Rocket Pharmaceuticals sells priority review voucher for $180M
Rocket Pharmaceuticals (NASDAQ:RCKT) has sold its Rare Pediatric Disease Priority Review Voucher for $180 million, significantly boosting its cash reserves to approximately $322.6 million, which is expected to fund operations into Q2 2028. The voucher was granted after the FDA approved Kresladi, their gene therapy for severe leukocyte adhesion deficiency-I. Despite a 24% year-to-date stock decline, analysts have raised price targets following the sale, while InvestingPro indicates the stock is undervalued and the company holds more cash than debt, though it is burning through cash quickly.
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Rocket Pharmaceuticals (NASDAQ: RCKT) has announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million. The PRV was granted by the FDA after the approval of KRESLADI™, Rocket’s gene therapy for severe LAD-I. This sale boosts Rocket's pro forma cash, cash equivalents, and investments to approximately $322.6 million, extending its operational runway into the second quarter of 2028.
Rocket Pharmaceuticals Closes $180 Million Priority Review Voucher Sale
Rocket Pharmaceuticals secured $180 million in non-dilutive cash proceeds by selling its Rare Pediatric Disease Priority Review Voucher (PRV), which was awarded for its recently approved gene therapy KRESLADI. This cash injection significantly boosts the company's financial position, increasing its pro forma cash and liquid investment balance to approximately $322.6 million. Management projects this capital will fund operations, pipeline manufacturing, and KRESLADI's commercial launch into the second quarter of 2028.
RCKT Technical Analysis & Stock Price Forecast
The technical analysis for Rocket Pharmaceuticals Inc (RCKT) indicates a "Strong Sell" consensus as of June 11, 2026. This is based on 12 technical signals, with 9 indicating sell and 3 indicating buy, and moving averages predominantly showing sell signals. Key indicators like MACD suggest a "Strong Sell," while the RSI is neutral, and the stock is trading below both its 60-day and 200-day moving averages.
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10
BofA Securities has reiterated its Buy rating for Rocket Pharmaceuticals (RCKT.US) and maintained its target price at $10. This indicates a continued positive outlook on the company's stock performance.
Rocket Pharmaceuticals (Nasdaq:RCKT) - Stock Analysis
This report provides a comprehensive stock analysis of Rocket Pharmaceuticals (Nasdaq: RCKT), a biotechnology company developing genetic therapies for rare diseases. It highlights the company's financial overview, including a market cap of US$300.3 million and a current share price of US$2.75, which is considered significantly undervalued by analysts, despite the company being unprofitable. The analysis covers recent news, insider transactions, clinical trial updates for key gene therapy programs like KRESLADI (LAD-I) and RP-A501 (Danon disease), and details on its pipeline, showing both progress and risks associated with its unprofitable status and insider selling.
RCKT: Cardiac gene therapy pipeline advances with pivotal trials and strong financial runway
Rocket Pharmaceuticals (RCKT) is shifting its focus to cardiovascular gene therapies, with ongoing pivotal trials for Danon and PKP2, and a new phase I trial for BAG3. The company has a strong financial runway extending into Q2 2028 and anticipates important regulatory and commercial updates this year and next. This information is based on an AI-generated summary of Rocket Pharmaceuticals' Goldman Sachs 47th Annual Global Healthcare Conference 2026 Audio Transcript.
RCKT - Rocket Pharmaceuticals Inc Stock Price and Quote
This article provides comprehensive stock information for Rocket Pharmaceuticals Inc (RCKT), including current quotes, financial metrics, analyst ratings, and a detailed list of recent news and insider transactions. The company is a clinical-stage biotechnology firm focused on gene therapies for rare pediatric diseases.
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $10
BofA Securities has reiterated its Buy rating on Rocket Pharmaceuticals (RCKT.US) and increased the target price to $10. This signals continued confidence from the firm in the company's financial prospects and stock performance.
Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $9.39, Implies 225% Upside
The average 12-month price target for Rocket Pharmaceuticals, Inc. (RCKT) stock has been raised to $9.39 by 11 analysts, implying a 225% upside based on the June 2nd closing price. Forecasts range from $3 to $16 per share. The consensus rating among 14 analysts has shifted to a "Buy," with six Buys, six Holds, and two Sells.
Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your Rights - Contact Levi & Korsinsky Before August 11, 2025
Levi & Korsinsky LLP has announced a class action securities lawsuit against Rocket Pharmaceuticals, Inc. (RCKT) for alleged securities fraud between September 17, 2024, and May 26, 2025. The lawsuit claims Rocket Pharmaceuticals made misleading statements regarding its RP-A501 clinical trial and failed to disclose critical protocol amendments and serious adverse events, including patient deaths. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky to learn about their rights to recovery before August 11, 2025.
Rocket Pharmaceuticals (NASDAQ: RCKT) exchanges options; 686,137 new grants
Rocket Pharmaceuticals (RCKT) completed an option exchange, accepting eligible options to purchase 1,376,937 shares (94.6% of eligible options) and granting 686,137 new options. The new options have an exercise price of $3.00 per share, which was the closing market price on May 26, 2026. A total of 157 eligible employees participated in the exchange, which effectively reduced outstanding option strikes while resetting exercise prices to current market levels.
Rocket Pharmaceuticals (RCKT) executive swaps underwater options for new $3.00 grants
Rocket Pharmaceuticals executive John Militello exchanged multiple "out-of-the-money" stock options for new grants with an exercise price of $3.00 per share on May 26, 2026. This option exchange cancelled older options with significantly higher strike prices, some up to $62.32, and replaced them with new options that align with the company's closing stock price on that date. The new grants, which include rights to purchase 9,091 and 51,509 shares, are subject to continued employment-based vesting.
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced its participation in the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026. CEO Gaurav Shah, M.D., will engage in a fireside chat, and management will hold investor meetings at both events. Webcasts for the presentations will be available on the company's investors website.
Rocket Pharmaceuticals CEO Shah sells $171,840 in stock
Gaurav Shah, CEO of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), sold 55,684 shares of common stock totaling approximately $171,840 to cover stock option exercise costs and associated taxes. This transaction followed his acquisition of 76,490 shares through a stock option exercise. Post-transactions, Shah directly holds over 1 million shares, with additional indirect holdings through his spouse and a trust.
Rocket Pharmaceuticals CEO Shah sells $171,840 in stock By Investing.com
Gaurav Shah, CEO of Rocket Pharmaceuticals, sold 55,684 shares of company stock for approximately $171,840 to cover stock option exercise costs and associated taxes. This transaction followed his acquisition of 76,490 shares through a stock option exercise. The company recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million, extending its cash runway, and analysts have raised price targets for the stock.
